The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2026 | The promise of GLP-1 receptor agonists for the prevention of acute leukemias in high-risk patients
In this video, Colton Jones, MD, University of Texas San Antonio, San Antonio, TX, discusses the potential of glucagon-like peptide-1 (GLP-1) receptor agonists for the prevention of acute leukemias. Dr Jones notes that his research group’s study found a significant risk reduction in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) in high-risk patients, including those with prior chemotherapy or genetic predisposition. This interview took place during the 2026 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
GLP-1s are the most talked about drugs today. They’ve gained a lot of attention for obesity risk reduction as well as for management of type 2 diabetes. However, there’s a lot of in vitro studies coming out showing a direct anti-cancer effect. And so our research group aimed to investigate GLP-1s because currently there are no FDA-approved medications for risk reduction of any sort of solid malignancy outside of breast cancer...
GLP-1s are the most talked about drugs today. They’ve gained a lot of attention for obesity risk reduction as well as for management of type 2 diabetes. However, there’s a lot of in vitro studies coming out showing a direct anti-cancer effect. And so our research group aimed to investigate GLP-1s because currently there are no FDA-approved medications for risk reduction of any sort of solid malignancy outside of breast cancer. And so this is a significant gap in the medical literature that we’re fulfilling with these studies. And so that was the aim of our study, to investigate whether or not these world-class, well-thought-of, groundbreaking medications could possibly have a risk reduction in multiple malignancies.
We did an abstract on GLP-1s for primary prevention of leukemias, focusing on risk reduction for acute and chronic leukemias. This has never been studied before in a high-risk population. And we defined high-risk population as those who got prior chemotherapy or patients with a known genetic predisposition to getting leukemias or other risk factors like obesity. What our study found was there was a 73% risk reduction in AML. Even greater in patients who got prior chemotherapy, there was about a 70-plus percent reduction in AML as well as ALL. And this is the first real-world signal showing risk reduction for leukemia.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
